title: TRAIL and targeting cancer cells: between promises and obstacles.
abstract: Targeting cancer cells is one of the challenges of current treatment strategies. TRAIL represents a promising therapeutic approach and over the past decades there was an increased interest in targeting TRAIL signaling to treat cancer. Indeed, TRAIL can specifically target cancer cells and exhibits very low cytotoxicity towards normal cells. However, rapidly accumulating experimental evidence has started to shed light on multiple factors which induce resistance against TRAIL in cancer cells. This resistance consists of various mechanisms including downregulation of death receptors and caspase-8 and overexpression of decoy receptors as well as antiapoptotic factors such as members of Bcl-2 family. Even if several studies focused on elucidating those resistance mechanisms, there still remain gray areas that need to be fully elucidated. Thus, therapeutic approaches could consist of targeting both resistance signaling pathways and TRAIL signaling to enhance TRAIL therapy efficiency.
authors.affiliation: Facult&eacute; de Pharmacie EA 1069 Laboratoire de Chimie des Substances Naturelles Limoges France limami&commat;hotmail.com.
authors.forename: Y
authors.initials: Y
authors.lastname: Limami
authors.affiliation: Facult&eacute; de Pharmacie EA 1069 Laboratoire de Chimie des Substances Naturelles Limoges France.
authors.forename: A
authors.initials: A
authors.lastname: Pinon
authors.affiliation: FC College Lahore Pakistan.
authors.forename: A
authors.initials: A
authors.lastname: Riaz
authors.affiliation: Facult&eacute; de Pharmacie EA 1069 Laboratoire de Chimie des Substances Naturelles Limoges France.
authors.forename: A
authors.initials: A
authors.lastname: Simon
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D015398:Signal Transduction; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000819:agonists / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human